Rodney Rodrigues de Assis Diego, Almeida Oliveira Alexandre, Luiz Porto Samuel, Aparecida Nonato Rabelo Rayane, Burgarelli Lages Eduardo, Corrêa Santos Viviane, Marques Milagre Matheus, Perdigão Fragoso Stenio, Martins Teixeira Mauro, Salgado Ferreira Rafaela, Renato Machado Carlos, Antônio Miranda Ferreira Lucas, Lucio Speziali Nivaldo, Beraldo Heloisa, Simão Machado Fabiana
Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil.
Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil.
Bioorg Chem. 2021 Aug;113:105018. doi: 10.1016/j.bioorg.2021.105018. Epub 2021 May 25.
Chagas disease (ChD), caused by Trypanosoma cruzi, remains a challenge for the medical and scientific fields due to the inefficiency of the therapeutic approaches available for its treatment. Thiosemicarbazones and hydrazones present a wide spectrum of bioactivities and are considered a platform for the design of new anti-T. cruzi drug candidates. Herein, the potential antichagasic activities of [(E)-2-(1-(4-chlorophenylthio)propan-2-ylidene)-hydrazinecarbothioamides] (C1, C3), [(E)-N'-(1-((4-chlorophenyl)thio)propan-2-ylidene)benzohydrazide] (C2), [(E)-2-(1-(4-, and [(E)-2-(1-((4-chlorophenyl)thio)propan-2-ylidene)hydrazinecarboxamide] (C4) were investigated. Macrophages (MOs) from C57BL/6 mice stimulated with C1 and C3, but not with C2 and C4, reduced amastigote replication and trypomastigote release, independent of nitric oxide (NO) and reactive oxygen species production and indoleamine 2,3-dioxygenase activity. C3, but not C1, reduced parasite uptake by MOs and potentiated TNF production. In cardiomyocytes, C3 reduced trypomastigote release independently of NO, TNF, and IL-6 production. C1 and C3 were non-toxic to the host cells. A reduction of parasite release was found during infection of MOs with trypomastigotes pre-incubated with C1 or C3 and MOs pre-stimulated with compounds before infection. Moreover, C1 and C3 acted directly on trypomastigotes, killing them faster than Benznidazole, and inhibited T. cruzi proliferation at various stages of its intracellular cycle. Mechanistically, C1 and C3 inhibit parasite duplication, and this process cannot be reversed by inhibiting the DNA damage response. In vivo, C1 and C3 attenuated parasitemia in T. cruzi-infected mice. Moreover, C3 loaded in a lipid nanocarrier system (nanoemulsion) maintained anti-T. cruzi activity in vivo. Collectively, these data suggest that C1 and C3 are candidates for the treatment of ChD and present activity in both the host and parasite cells.
恰加斯病(ChD)由克氏锥虫引起,由于现有治疗方法效率低下,对医学和科学领域来说仍是一项挑战。缩氨基硫脲和腙具有广泛的生物活性,被认为是设计新型抗克氏锥虫候选药物的一个平台。在此,对[(E)-2-(1-(4-氯苯硫基)丙-2-亚基)-肼基甲硫酰胺](C1、C3)、[(E)-N'-(1-((4-氯苯基)硫基)丙-2-亚基)苯甲酰肼](C2)、[(E)-2-(1-(4-……]以及[(E)-2-(1-((4-氯苯基)硫基)丙-2-亚基)肼基甲酰胺](C4)的潜在抗恰加斯病活性进行了研究。用C1和C3刺激C57BL/6小鼠的巨噬细胞(MOs),而非C2和C4,可减少无鞭毛体复制和锥鞭毛体释放,这与一氧化氮(NO)、活性氧产生以及吲哚胺2,3-双加氧酶活性无关。C3而非C1可减少MOs对寄生虫的摄取并增强肿瘤坏死因子(TNF)的产生。在心肌细胞中,C3可独立于NO、TNF和白细胞介素-6(IL-6)的产生减少锥鞭毛体释放。C1和C3对宿主细胞无毒。在用C1或C3预孵育的锥鞭毛体感染MOs以及在感染前用化合物预刺激MOs的过程中,发现寄生虫释放减少。此外,C1和C3直接作用于锥鞭毛体,比苯并硝唑更快地杀死它们,并在其细胞内周期的各个阶段抑制克氏锥虫增殖。从机制上讲,C1和C3抑制寄生虫复制,并且该过程不能通过抑制DNA损伤反应来逆转。在体内,C1和C3可减轻克氏锥虫感染小鼠的寄生虫血症。此外,负载在脂质纳米载体系统(纳米乳剂)中的C3在体内保持抗克氏锥虫活性。总体而言,这些数据表明C1和C3是治疗恰加斯病的候选药物,并且在宿主细胞和寄生虫细胞中均具有活性。